Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN901 in Relapsed/Refractory Pediatric Solid Tumors
NCT02452554Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorvotuzumab mertansine in Wilms' tumor, rhabdomyosarcoma (RMS), neuroblastoma and 3 more, sponsored by Children's Oncology Group. Primary endpoints: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 up to 18 weeks and Incidence of Toxicities of Lorvotuzumab Mertansine up to 12 months. Started Oct 2015; status: completed.
02
Drugs
lorvotuzumab mertansine
03
Conditions
Wilms' tumorrhabdomyosarcoma (RMS)neuroblastomaPleuropulmonary blastoma (PPB)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02452554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452554.